COMMUNIQUÉS West-GlobeNewswire

A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
09/10/2026
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study [...]
T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing
09/10/2026
Austin, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- T·Time Health Inc. , the telehealth brand at ttime.men, has launched cash-pay compounded injectable semaglutide and tirzepatide with one published rate regardless of [...]
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
09/10/2026
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/10/2026
BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
09/10/2026
Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and [...]
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
09/10/2026
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Kylo Peptides Introduces Lifetime 50% Member Pricing for Peptide Research Buyers
09/10/2026
The new membership pricing program gives eligible research buyers 50% off standard pricing on qualifying Kylo Peptides research products. SHERIDAN, WYOMING, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https:// [...]
NTG Nordic Transport Group A/S - Q3 2026 Conference Call
09/10/2026
NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference call will be held on [...]
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
09/10/2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching [...]
TherapiAI Showcases Agentic AI Platform for Biopharma at BioJapan 2026
09/10/2026
YOKOHAMA, Japan, Oct. 09, 2026 (GLOBE NEWSWIRE) -- TherapiAI, a Taipei-based developer of AI agents for drug development and manufacturing, showcased its Biopharma AI Operating Layer at BioJapan 2026 this week as it [...]
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
09/10/2026
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50 [...]
TRexBio Announces Pricing of Initial Public Offering
09/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
09/10/2026
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the [...]
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
08/10/2026
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla [...]
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
08/10/2026
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in [...]
Initiation of buy-back programme
08/10/2026
ANNOUNCEMENT NO. 320 8 October 2026 The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 8 October 2026. The authorisation is [...]
Clever Care Health Plan Achieves 4.5-Star Medicare Advantage Rating from CMS for Star Year 2027
08/10/2026
The rating arrives as Clever Care achieves significant growth and unveils its new benefits for 2027 HUNTINGTON BEACH, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clever Care Health Plan , a culturally competent and [...]
Alignment Healthcare Earns 4 Stars or Higher for Six of Seven Eligible Medicare Advantage Contracts in CMS 2027 Star Ratings
08/10/2026
Three contracts achieve 4.5-Star ratings as Alignment remains focused on delivering high-quality, coordinated care for seniors ORANGE, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) [...]
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
09/10/2026
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well- [...]

Pages